Research programme: solid tumors therapeutics - Fusion Pharmaceuticals
Latest Information Update: 10 Jun 2024
At a glance
- Originator Fusion Pharmaceuticals
- Class Antineoplastics; Drug conjugates; Radioisotopes; Radiopharmaceuticals
- Mechanism of Action Ionising radiation emitters
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Research Solid tumours
Most Recent Events
- 04 Jun 2024 Fusion Pharmaceuticals has been acquired by AstraZeneca
- 09 Nov 2021 Early research in Solid tumours in Canada and USA (unspecified route) as of November 2021 (Fusion Pharmaceuticals pipeline; November 2021)